Ms related abstracts ens june 2013 barcelona

Search result

Search Result: Session Chair

SATURDAY, JUNE 08, 2013

SUNDAY, JUNE 09, 2013

MONDAY, JUNE 10, 2013

TUESDAY, JUNE 11, 2013

Search Result: Abstracts

SATURDAY, JUNE 08, 2013

11:55 - 12:15 / TEVA PHARMACEUTICALS EUROPE BV SATELLITE SYMPOSIUM : EMERGING INSIGHTS IN MULTIPLE SCLEROSIS: RE-EVALUATING THE TREATMENT ALGORITHM / ROOM A

13:30 - 14:15 / TEACHING COURSE 5 : LONGITUDINAL MONITORING WITH NEUROIMAGING TECHNIQUES / ROOM E

Personal programme DisplayPrint current view print

11:50 - 13:20

Teva Pharmaceuticals Europe BV Satellite Symposium: Emerging insights in Multiple Sclerosis: re-evaluating the treatment algorithmRoom A

A. Rovira (Barcelona, ES)

P. Rieckmann (Bamberg, DE)

11:30 - 12:30

Poster Session 1: Multiple Sclerosis: clinical aspects IPoster Area

K. Fink (Stockholm, SE)

13:45 - 15:15

Oral Session 2: Multiple Sclerosis I: TherapeuticsRoom D

X. Montalban (Barcelona, ES)

L. Kappos (Basel, CH)

15:45 - 17:15

Joint ENS-SEN Symposium: Role of antibodies in Multiple SclerosisRoom D

O. Fernandez (Malaga, ES)

P. Soelberg Sørensen (Copenhagen, DK)

11:30 - 12:30

Poster Session 2: Multiple Sclerosis: clinical aspects IIPoster Area

H.-P. Hartung (Düsseldorf, DE)

13:30 - 15:00

Oral Session 13: Multiple Sclerosis II: pathology and pathogenesisRoom A

G. Comi (Milan, IT)

O. Ciccarelli (London, GB)

15:30 - 17:00

Oral Session 18: Multiple Sclerosis III: OtherRoom A

I. Milonas (Athens, GR)

H.-P. Hartung (Düsseldorf, DE)

17:30 - 18:30

Poster Session 3: Multiple Sclerosis: clinical aspects IIIPoster Area

J. Sastre-Garriga (Barcelona, ES)

09:00 - 11:00

Symposium: Personalised treatment in Multiple SclerosisPlenary Hall

G. Comi (Milan, IT)

11:30 - 12:30

Poster Session 4: Multiple Sclerosis: pathology and pathogenesisPoster Area

O. Fernández (Malaga, ES)

13:30 - 17:00

Teaching Course 17: Measuring heterogeneity in Multiple Sclerosis: the MRI perspectiveRoom A

M. Filippi (Milan, IT)

J. Geurts (Amsterdam, NL)

Multiple Sclerosis: Changing concepts, new targetsF. Barkhof (Amsterdam, NL)

http://registration.akm.ch/einsicht_iframe.php?XNMASKEN_ID=300&XNKONGRESS_ID=183&XNSPRACHE_ID=2&XNSESSION_ID=15079











http://registration.akm.ch/einsicht_iframe.php?XNABSTRACT_ID=174940&XNSPRACHE_ID=2&XNKONGRESS_ID=183&XNMASKEN_ID=900

18:15 - 18:45 / PRESIDENTIAL SYMPOSIUM : SLEEP FOR THE BRAIN, BY THE BRAIN / PLENARY HALL

18:45 - 19:15 / PRESIDENTIAL SYMPOSIUM : SLEEP FOR THE BRAIN, BY THE BRAIN / PLENARY HALL

SUNDAY, JUNE 09, 2013

11:30 - 12:30 / POSTER SESSION 1 : MULTIPLE SCLEROSIS: CLINICAL ASPECTS I / POSTER AREA

11:30 - 12:30 / POSTER SESSION 1 : NEUROIMAGING / POSTER AREA

11:30 - 12:30 / POSTER SESSION 1 : NEUROREHABILITATION / POSTER AREA







Multiple SclerosisF. Fazekas (Graz, AT)

Sleep-wake disorders as first/main manifestation of a neurological disorderJ. Santamaria (Barcelona, ES)

Sleep-wake disorders as modulators of the outcome of neurological disordersC.L. Bassetti (Berne, CH)

Relationship between early disease activity and long-term clinical outcome: results from the phase 3 TRANSFORMS study extension at 4.5 years in

relapsing-remitting multiple sclerosisH.-P. Hartung, F. Barkhof, G. Comi, L. Kappos, B. Khatri, X. Montalban, J. Pelletier, E.

Kornyeyeva, D. Piani Meier, S. Ritter, P. von Rosenstiel, D. Tomic, J. Cohen (Düsseldorf, DE;

Amsterdam, NL; Milan, IT; Basel, CH; Milw aukee, US; Barcelona, ES; Marseille, FR; East

Hanover, US; Cleveland, US)

Functional and structural disruption of the precuneus contributes to cognitive impairment in paediatric multiple sclerosisM. Filippi, M. Absinta, M.P. Amato, A. Ghezzi, L. Moiola, A. Fiorino, P. Veggiotti, G. Comi, M.A.

Rocca and the MS and Neuroimaging Study Groups of the Italian Neurological Society

Sustainable effects of a 12-week patient education programme in multiple sclerosis patients: a qualitative analysisS. Kersten, J. Drosselmeyer, C.T. Haas (Saarbrücken, Idstein, DE)

Association of improvement in fatigue with improvement in depression and sleepiness in natalizumab-treated multiple sclerosis (MS) patients: results from

the TYNERGY studyI.-K. Penner, E.G. Celius, S. Fuchs, K. Schreiber, S. Berkö, J. Sun, E. Falk, A. Svenningsson

(Basel, CH; Oslo, NO; Graz, AT; Copenhagen, DK; Upplands Väsby, SE; Weston, US; Umeå,

SE)

Clinical and instrumental predictors of efficacy of natalizumab therapy in the course of multiple sclerosis: a retrospective study from a single centreV. Lo Re, G. Salemi, P. Ragonese, M. Lo Re, M.A. Mazzola, S. Realmuto, G. Savettieri (Palermo,

IT)

Natalizumab saturation: potential biomarker for individual duration of treatment holiday after natalizumab withdrawalP. Wipfler, A. Harrer, G. Pilz, K. Oppermann, S. Afazel, E. Haschke-Becher, E. Trinka, J. Kraus

(Salzburg, AT)

Adherence to, and effectiveness of, treatment with subcutaneous interferon beta-1a in relapsing multiple sclerosis patients using RebiSmart™ for self-

injection: one-year interim results of an international, prospective, observational studyA. Bayas, J.-C. Ouallet, B. Kallmann, U. Fulda, K. Marhardt (Augsburg, DE; Bordeaux, FR;

Bamberg, Darmstadt, DE; Geneva, CH)

Natalizumab treatment for multiple sclerosis: Middle East and North Africa regional recommendations for patient selection and monitoringR. Alroughani, H. Aref, S. Bohlega, I. Al Sherooqi, M. Dahdaleh, I. Feki, M. Jumah, M. Al-Kaw i,

S. Koussa, M. Sahraian, B. Yamout (Kuw ait, KW; Cairo, EG; Riyadh, SA; Manama, BH; Amman,

JO; Sfax, TN; Beirut, LB; Tehran, IR)



















11:30 - 12:30 / POSTER SESSION 1 : INFLAMMATORY AND MYASTHENIA / POSTER AREA

11:30 - 12:30 / POSTER SESSION 1 : PRECLINICAL NEUROBIOLOGY / POSTER AREA

11:30 - 12:30 / POSTER SESSION 1 : NEUROOPHTHALMOLOGY AND BALANCE / POSTER AREA


Health-related quality of life over time of patients with multiple sclerosis treated with interferon beta-1a: the COMPARE studyB.G. Vickrey, L. Lee, F. Moore, K. Fortin (Los Angeles, US; Toronto, CA; Montréal, US;

Montréal, CA)

Comparable efficacy of immunomodulatory treatment of relapsing-remitting multiple sclerosis (RRMS) in daily practice: the ASSET (AVONEX assessment in

multiple sclerosis therapy) study, an observational study in 1343 patientsM. Marziniak, K. Taipale, K. Rehberg-Weber, C. Wernsdörfer on behalf of the ASSET study

group

Successful desensitization in a patient with hypersensitivity reaction to natalizumab: a case reportM. Bouktsi, A. Manikas, M. Zande, I. Milonas (Thessaloniki, GR)

Natalizumab rechallenge in multiple sclerosis patients: postponing the unavoidable?L. Ferrè, F. Sangalli, L. Moiola, M. Radaelli, V. Barcella, M. Rodegher, B. Colombo, V. Martinelli,

G. Comi (Milan, IT)

Abnormally severe immune reconstitution inflammatory syndrome (IRIS) in a multiple sclerosis (MS) patient with natalizumab-associated progressive

multifocal leukoencephalopathy (PML)A. Calvi, M. De Riz, A.M. Pietroboni, L. Ghezzi, A. Arighi, G.G. Fumagalli, V. Maltese, G. Comi,

D. Galimberti, E. Scarpini (Milan, IT)

Persistence, adherence, quality of life, and treatment satisfaction in patients treated with the AVONEX® PEN^TM: an interim analysis of PERSISTB. Sperling, S. Slaw ka, C. Ghaus, X. You on behalf of the PERSIST Study Group

Associations between baseline factors and on-treatment relapses in natalizumab-treated patients with relapsing-remitting multiple sclerosis in the

TYSABRI® (natalizumab) observational programmeH. Wiendl, H. Butzkueven, L. Kappos, F. Pellegrini, M. Trojano, A. Zhang, S. Belachew

(Münster, DE; Victoria, AU; Basel, CH; Chieti, Bari, IT; Weston, US)

A prospective, open-label, single-arm clinical trial of the effects of natalizumab on measures of ambulation in relapsing-remitting multiple sclerosis

patients: the TIMER studyN. Voloshyna, T. Nechrych, X. You, S. Belachew , D. Paes (Kharkiv, Lviv, UA; Weston, US)

Clinical and neuroradiological evaluation in neurosarcoidosisG. Gözbatik-Celik, U. Uygunoglu, D. Uluduz, S.N. Yeni, S. Saip, A. Siva (Istanbul, TR)

Intrathecal transplantation of neural stem/precursor cells derived from induced pluripotent stem cells improves the clinical and neuropathological outcome

of a mouse model of multiple sclerosisC. Laterza, A. Merlini, D. De Feo, F. Ruff ini, E. Brambilla, A. Lombardo, M. Onorati, E. Cattaneo,

G. Comi, G. Martino (Milan, IT)

A preliminary longitudinal study of the retinal nerve fibre layer in clinically isolated syndromes (CIS)C. Oreja-Guevara, S. Noval, A. Royo, B. Chamorro, J. Alvarez-Linera (Madrid, ES)

Clinical management of high-risk patients with relapsing-remitting multiple sclerosis (MS) treated with natalizumab



















11:30 - 12:30 / POSTER SESSION 1 : NEUROIMAGING / POSTER AREA


11:30 - 12:30 / POSTER SESSION 1 : INFLAMMATORY AND MYASTHENIA / POSTER AREA



K.H. Vo, L. Stazzone, N. Drago, H. Nguyen, G. Buckle (Boston, Brookline, US)

Follow-up of multiple sclerosis (MS) patients after natalizumab interruption. Clinical and MRI findings. Switching to treatment with fingolimodM.E. Evangelopoulos, E. Andreadou, C. Deligianni, G. Saltogiannis, I. Chasalevris, V. Chaina, C.

Kilidireas (Athens, GR)

Seroconversion rates to JC virus (JCV) in multiple sclerosis patients is higher than previously reportedG. Izquierdo, M. Rus, M.D. Paramo, J.L. Peña, L. Dinca, S. Perez, G. Navarro, M. Lucas (Seville,

ES)

Patient and nurse assessment of the ExtaviJect® 30G device for subcutaneous self-injection of interferon beta-1b for multiple sclerosis: a prospective

European studyG. Boeru, I. Milanov, K. Kmetska, F. De Robertis, S. Rojas-Farreras, A. Kulla, M. Tomlinson

(Bucharest, RO; Sofia, BG; Lecce, IT; Barcelona, ES; Basel, CH)

Patient adherence to subcutaneous interferon beta-1a delivered via the electronic self-injection device RebiSmart: an observational, retrospective study in

the United Kingdom and IrelandL. Parkes, K. Marhardt, H. Willis, A.M. Larkin (Feltham, GB; Geneva, CH; Chelmsford, GB;

Dublin, IE)

Natalizumab-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients: survival and functional outcome when asymptomatic at

diagnosisT. Dong-Si, S. Richman, G. Bloomgren, M. Wenten, J. Philip, S. Datta, J. McIninch, C. Bozic, B.

Ticho, N. Richert (Weston, US)

Improvement in quality of life outcomes with prolonged-release fampridine treatment: six month interim analysis of the ENABLE studyR. Macdonell, G. Nagels, P.S. Sorensen, D. Laplaud, C. Pozzilli, B. de Jong, A.M. Silva, R.

Nicholas, M. Niedhammer, J. Gaebler, S. Agarw al, J. Potts (Heidelberg, AU; Melsbroek, BE;

Copenhagen, DK; Nantes, FR; Rome, IT; Nijmegen, NL; Porto, PT; London, GB; Oldenburg, DE;

Weston, US)

Retinal nerve fibre layer and brain atrophy in relapsing-remitting multiple sclerosis: a longitudinal correlation studyA. Bisecco, A. Gallo, M. Lanza, R. Sacco, S. Borrelli, L. Lavorgna, M. Cirillo, S. Bonavita, F.

Esposito, G. Tedeschi (Naples, IT)

Natalizumab is effective in patients with active relapsing-remitting multiple sclerosis: a Middle Eastern experienceR. Alroughani, J. Al Hashel, S. Ahmed, A. Thussu (Kuw ait, KW)

MTCH1 antibodies in neuromyelitis optica patients with or without aquaporin-4 antibodiesA. Çoban, F. Çavus, C. Ulusoy, S. Turan, B. Vural, R. Türkoglu, M. Kürtüncü, M. Eraksoy, G.

Akman-Demir, E. Tüzün (Istanbul, TR)

An integrated analysis of safety and tolerability of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis from phase 2 and 3

placebo-controlled studiesJ.T. Phillips, R.J. Fox, R. Gold, E. Havrdova, L. Kappos, K. Raghupathi, H. Yuan, V. Viglietta, S.I.

Sheikh, K.T. Daw son, M. Novas, M.T. Sw eetser, K. Selmaj (Dallas, Cleveland, US; Bochum, DE;

Prague, CZ; Basel, CH; Weston, US; Lodz, PL)

An integrated analysis of the clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis from the phase 3 DEFINE

and CONFIRM studies














13:45 - 14:00 / ORAL SESSION 2 : MULTIPLE SCLEROSIS I: THERAPEUTICS / ROOM D

14:00 - 14:15 / ORAL SESSION 3 : NEUROPHYSIOLOGY / ROOM E






17:00 - 17:15 / ORAL SESSION 7 : NEURO-ONCOLOGY AND MISCELLANEOUS / ROOM E

MONDAY, JUNE 10, 2013

09:45 - 10:00 / ORAL SESSION 10 : NEUROIMAGING / ROOM C

R.J. Fox, D.H. Miller, J.T. Phillips, D.L. Arnold, K. Selmaj, M. Yang, R. Zhang, K.T. Daw son, V.

Viglietta, S.I. Sheikh, R. Gold (Cleveland, US; London, GB; Dallas, US; Montreal, CA; Lodz, PL;

Weston, US; Bochum, DE)

Safety, tolerability and patient evaluation of peginterferon beta-1a administered via a single-use autoinjector in relapsing multiple sclerosis: data from the

Phase 3b ATTAIN sub-studyS. Hung, A. Deykin, A. Seddighzadeh, S. Liu, B. Sperling, P. Calabresi (Cambridge, Baltimore,

US)

Immunomodulatory effects of a new CB2-selective cannabinoid agonist on T-cells from multiple sclerosis patientsP. Annunziata, C. Cioni, L. De Santi, C. Mugnaini, S. Pasquini, F. Corelli (Siena, IT)

Clinical efficacy and safety of peginterferon beta-1a in relapsing multiple sclerosis: data from the pivotal phase 3 ADVANCE studyB. Kieseier, D.L. Arnold, L. Balcer, A. Boyko, J. Pelletier, A. Deykin, S. Hung, A. Seddighzadeh,

S. Liu, Y. Zhu, B. Sperling, P. Calabresi (Düsseldorf, DE; Montreal, CA; Philadelphia, US;

Moscow , RU; Marseille, FR; Cambridge, Baltimore, US)

Evoked potentials predict disease-modifying treatment response in multiple sclerosisL. Leocani, M. Bianco, G. Di Maggio, S. Medaglini, J. Gonzalez-Rosa, R. Chieffo, U. Del Carro,

L. Moiola, V. Martinelli, G. Comi (Milan, IT)

Use of JC virus antibody index to stratify risk of progressive multifocal leukoencephalopathy in natalizumab-treated patients with multiple sclerosisT. Plavina, M. Subramanyam, G. Bloomgren, S. Richman, A. Pace, S. Lee, B. Schlain, D.

Campagnolo, B. Ticho (Weston, US)

An integrated analysis of the clinical and neuroradiological effect of BG-12 (dimethyl fumarate) in subgroups of patients with relapsing-remitting multiple

sclerosis from the phase 3 DEFINE and CONFIRM studiesA. Bar-Or, R.J. Fox, R. Gold, D.H. Miller, D.L. Arnold, J. O'Gorman, M. Yang, S.I. Sheikh, V.

Viglietta, K.T. Daw son, M. Hutchinson (Montreal, CA; Cleveland, US; Bochum, DE; London, GB;

Weston, US; Dublin, IE)

Alemtuzumab improves disability by month 6 independent of relapse history in relapsing-remitting multiple sclerosis patients: CARE-MS IIO. Fernandez, D.L. Arnold, J.A. Cohen, A.J. Coles, C. Confavreux, E.J. Fox, H.-P. Hartung, E.

Havrdova, K. Selmaj, H. Weiner, C.L. Tw yman, T. Miller, S.L. Lake, D.H. Margolin, M.A. Panzara,

D.A.S. Compston for the CARE-MS II Investigators

Catastrophic multiple sclerosis rebound after natalizumab treatment discontinuationC. Tur, M. Tintoré, Á. Vidal-Jordana, J. Rio, A.C. Wing, B. Canneti, M. Torres, M.J. Arevalo, J.

Castillo, I. Galan, R. Horno, M.J. Vicente, M.I. Martin, M. Comabella, À. Rovira, J. Sastre-Garriga,

X. Montalban (Barcelona, ES)

Prognostic factors for long-term outcomes in relapsing-remitting multiple sclerosis: exploratory analysis of 15-year data from the PRISMS studyL. Kappos, B. Uitdehaag, J. Kuhle, D. Issard, F. Casset-Semanaz (Basel, CH; Amsterdam, NL;

Geneva, CH)

Professionals’ opinions on the physical factors affecting quality of life in multiple sclerosis and motor neurone disease: pilot work from the Trajectories of

Outcomes in Neurological Conditions studyB. O'Sullivan, N. Rose, J. Griff iths, C.A. Young on behalf of the Trajectories of Outcome in

Neurological Conditions (TONiC) Study Group

High resolution magnetization transfer imaging to study the specific contribution of white matter and grey matter to disability in multiple sclerosis














11:30 - 12:30 / POSTER SESSION 2 : MULTIPLE SCLEROSIS: CLINICAL ASPECTS II / POSTER AREA



11:30 - 12:30 / POSTER SESSION 2 : DEMENTIA I: TREATMENT AND BIOMARKER / POSTER AREA






A. Papadopoulou, M. Amann, M. Andelova, N. Müller-Lenke, Y. Naegelin, C. Stippich, E.W.

Radue, O. Bieri, L. Kappos, T. Sprenger (Basel, CH)

Abnormalities of the brain connectome in patients with multiple sclerosisM. Filippi, P. Valsasina, S. Sala, A. Meani, A. Falini, G. Comi, M.A. Rocca (Milan, IT)

Structural correlates of abnormalities of cervical cord functional MRI activity in patients with multiple sclerosisM.A. Rocca, P. Valsasina, M. Copetti, D. Caputo, M. Absinta, M. Filippi (Milan, San Giovanni

Rotondo, IT)

Safety and cardiac outcomes of fingolimod 0.5 mg in the Italian cohort from the 4-month, open-label, single-arm, multi-centre FIRST studyG. Marrosu, G. Comi, S. Ruggieri, A. Francia, S. Cottone, D. Maimone, R. Turrini, A. Sinha, P.

Von Rosenstiel, D. Tomic (Cagliari, Milan, Pozzilli, Rome, Palermo, Catania, Orrigio, IT;

Hyderabad, IN; Basel, CH)

Autologous mesenchymal stem cell transplantation in multiple sclerosisY. Motuzova, M. Zafranskaya, D. Nizheharodova, A. Borisov, I. Svirid, D. Balvanovich, T.

Kachan, M. Minzer, E. Selezneva, A. Fedulov (Minsk, BY)

Impact of a single relapse in disability and progression in multiple sclerosis: a random forest approachL.A. Rodríguez de Antonio, I. Pulido-Valdeolivas, D. Gómez-Andrés, M.J. Aguilar-Amat, A.

Cruz-Herranz, I. González-Suárez, A. Tallón-Barranco, E. Díez-Tejedor (Madrid, ES)

Fixed-dose dextromethorphan and quinidine is effective in the treatment of pseudobulbar affect due to neurodegenerative conditions: a case seriesD. Kantor (Ponte Vedra, US)

Overall safety and relapse outcomes in fingolimod-treated patients previously exposed to natalizumab in the 4-month, open label FIRST studyG. Comi, R. Gold, F. Dahlke, A. Sinha, P. Von Rosenstiel, D. Tomic, L. Kappos (Milan, IT;

Bochum, DE; Basel, CH; Hyderabad, IN)

Optical coherence tomography (OCT) study in multiple sclerosis patients treated with fingolimodC. Oreja-Guevara, M. Capote Díez, B. Chamorro Hernández, S. Noval Martin (Madrid, ES)

Safety and efficacy of intravenous injection of autologous bone marrow-derived mesenchymal stem cell in patients with multiple sclerosis: a double blind

randomized semi-crossover clinical trial: preliminary report 1 - safety issuesS.M. Nabavi, N. Aghdami, L. Arab, A. Hamzeloo (Tehran, IR)

Long-term effects of cognitive rehabilitation in multiple sclerosis: 12-month follow-upA. Altinkaya, I. Guclu, E. Kurt, A. Bingöl, A. Soysal, D. Yandim Kuscu, D. Kirbas, B. Topcular

(Istanbul, TR)

Early mobility impairment: bridging the communication gap between people with multiple sclerosis and their healthcare providersB. Anderseck, P. Van Asch, J. Johnson, S. Agarw al, S. Hudgens, L. Humphrey, R. Medcalf, T.

Ziemssen (Valens, CH; Kontich, BE; Weston, MA, Weston, Boston, US; Cheshire, GB;






















11:30 - 12:30 / POSTER SESSION 2 : CEREBROVASCULAR DISORDERS: SEMIOLOGY AND CASE REPORTS / POSTER AREA

Dresden, DE)

Cardiac effects of fingolimod in patients with multiple sclerosisB.L. Hughes, M. Cascione, K. McCague, L. Pestreich, L. Schofield, E. Kim, L.M. Barbato (Des

Moines, Tampa, East Hanover, US)

Alemtuzumab improves quality of life compared to SC IFNB-1a in CARE-MS IIR. Arroyo, D.L. Arnold, J.A. Cohen, A.J. Coles, C. Confavreux, E.J. Fox, H.-P. Hartung, E.

Havrdova, K. Selmaj, H. Weiner, C.L Tw yman, T. Miller, A. Boscoe, S.L Lake, D.H. Margolin, M.

Panzara, D.A.S. Compston for the CARE-MS II Investigators

No effect on incidence of infection after therapy switch to fingolimodC. LaGanke, D.R. Wynn, K. McCague, L.M. Barbato, R. Hashmonay (Cullman, Northbrook, East

Hanover, US)

Teriflunomide hepatic safety results: pooled data from three placebo-controlled studiesC. Confavreux, T.P. Olsson, G. Comi, M.S. Freedman, A. Miller, J.S. Wolinsky, L. Kappos, J.-L.

Delhay, H. Li, P. Truff inet, P. O’Connor (Lyon, FR; Stockholm, SE; Milan, IT; Ottaw a, CA; New

York, Houston, US; Basel, CH; Chilly Mazarin, FR; Bridgew ater, US; Toronto, US)

Exploring the impact of teriflunomide on immune cells in patients with relapsing multiple sclerosis: design of the Teri-Dynamic studyF. Menguy-Vacheron, R. Varona, A. Posevitz-Fejfar, V. Posevitz, L. Klotz, H. Wiendl (Chilly

Mazarin, FR; Münster, DE)

Improved quality of life after therapy change to fingolimodH. Crayton, S.F. Hunter, C. Huffman, N. Agashivala, L. Schofield, K. McCague, L.M. Barbato

(Vienna, Franklin, Tampa, East Hanover, US)

Influence of the mode of walk on walking speed in multiple sclerosis: are you walking comfortably?R. Phan-Ba, G. Delrue, S. Pierard, E. Lommers, P. Calay, M. Vandroogenbroeck, V. Delvaux

(Liège, BE)

Improvement in physical disability with fingolimod: post-hoc analyses of FREEDOMS and TRANSFORMSN. Bergvall, N. Sfikas, P. Chin, D. Tomic, G. Cutter (Basel, CH; East Hanover, US; Birmingham,

US)

Motor sequence learning in relapsing-remitting multiple sclerosis (MS) patientsN. Zahiri, I. Abdollahi, A.M. Arab, S.M. Nabavi (Tehran, IR)

Cognitive impairment in relapsing-remitting multiple sclerosis patientsA. Altinkaya, E. Ozcan, D. Kuscu, E. Kurt, A. Bingöl, D. Kirbas, B. Topcular (Istanbul, TR)

A rare case of cerebroretinal vasculopathy caused by a novel Trex 1 mutationE. Schuh, P. Lohse, T. Kümpfel (Munich, Singen, DE)












11:30 - 12:30 / POSTER SESSION 2 : MIGRAINE AND PAIN / POSTER AREA











Impact of chronic pain on the quality of life of patients with multiple sclerosisC. Voiticovschi-Iosob, I. Moldovanu (Chisinau, MD)

Long term efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis previously treated with interferon beta-1a or disease modifying

therapies: a post-hoc analysis of the TRANSFORMS 4.5 year extension studyX. Montalban, F. Barkhof, G. Comi, H.-P. Hartung, L. Kappos, B. Khatri, J. Pelletier, E.

Kornyeyeva, S. Ritter, P. von Rosenstiel, J. Cohen (Barcelona, ES; Amsterdam, NL; Milan, IT;

Düsseldorf, DE; Basel, CH; Milw aukee, US; Marseille, FR; East Hanover, US; Cleveland, US)

The relationship between dehydroepiandrosterone and cortisol with fatigue and depression in multiple sclerosisS. Rashidfard, M. Moghadasi, A. Moeini, A. Rahimi, M. Edalatmanesh (Fars, Shiraz, IR)

MRI timings and their impact on new T2 lesions’ ability to predict treatment failure in multiple sclerosis (MS)C. Tur, À. Rovira, J. Rio, M. Tintore, J. Sastre-Garriga, C. Auger, J. Castillo, Á. Vidal-Jordana, I.

Galan, M.J. Arevalo, R. Mitjana, E. Anglada, G. Arrambide, C. Nos, M. Comabella, X. Montalban

(Barcelona, ES)

Individualized dosing in the treatment of relapsing-remitting multiple sclerosis (RRMS) using S1P receptor-modulating therapies: a simulation studyF. Mercier (Wintzenheim, FR)

Prognostic factors for the early development of clinically definite multiple sclerosis in patients with clinically isolated syndromesV. Martinelli, G. Dalla Costa, G. Di Maggio, B. Colombo, D. Dalla Libera, L. Leocani, R. Furlan, M.

Filippi, G. Comi (Milan, IT)

Impact of expanded disability status scale (EDSS) on oral health in multiple sclerosis patients: a preliminary studyS. Canbaz Kabay, H. Hatipoglu, M. Gungor Hatipoglu, H. Ozden (Kutahya, Eskisehir, TR)

Treatment experience, burden and unmet needs (TRIBUNE) in multiple sclerosis (MS): Turkish dataR. Karabudak, K. Karampampa, A. Gustavsson (Ankara, TR; Stockholm, SE)

Intrathecal combined methotrexate and dexametasone therapy in progressive multiple sclerosisM. Volpini, C. Monaldini, M. Stumpo, S. Guttmann (Cailungo, SM)

Long term follow-up of autologous stem cell transplantation in multiple sclerosis patientsM. Radaelli, L. Moiola, R. Greco, V. Martinelli, F. Sangalli, P. Rossi, L. Ferrè, M. Comola, P.

Vezzulli, J. Peccatori, F. Ciceri, G. Comi (Milan, IT)

Lymphocyte counts and infection risk among relapsing-remitting multiple sclerosis patients treated with alemtuzumab (CARE-MS II)E. Havrdova, D.L. Arnold, J.A. Cohen, A.J. Coles, C. Confavreux, E.J. Fox, H.-P. Hartung, K.W

Selmaj, H.L. Weiner, T. Miller, C.L. Tw yman, S.L. Lake, D.H Margolin, M.A. Panzara, D.A.S.

Compston for the CARE-MS II Investigators












13:30 - 13:45 / ORAL SESSION 13 : MULTIPLE SCLEROSIS II: PATHOLOGY AND PATHOGENESIS / ROOM A





15:30 - 15:45 / ORAL SESSION 18 : MULTIPLE SCLEROSIS III: OTHER / ROOM A





16:45 - 17:00 / ORAL SESSION 21 : NEUROREHABILITATION / ROOM F


Characterization of individual IgM oligoclonal band antibodies from the cerebrospinal fluid (CSF) of multiple sclerosis patients to identify their antigensE. Beltrán, B. Obermeier, F. Coret, M. Simó-Castelló, F.C. Pérez-Miralles, R. Hohlfeld, B.

Casanova, K. Dornmair (Munich, DE; Valencia, ES)

Aquaporin-1 autoantibodies in patients with neuromyelitis optica spectrum disordersJ.S. Tzartos, C. Stergiou, K. Kilidireas, P. Zisimopoulou, T. Thomaidis, S. Tzartos (Athens, GR)

Construction of an antibody phage display library from B-cells infiltrating brain tissue of people with progressive multiple sclerosisC. Maggiore, G. Giovannoni, J. Martin, A. Nissim (London, GB)

Semaphorin 7A and its receptor expression in multiple sclerosis lesionsE. Martínez-Sáez, C. Costa, A. Gutiérrez, A. Ortega-Aznar, S. Ramón y Cajal, X. Montalban, C.

Espejo (Barcelona, ES)

Cerebrospinal fluid (CSF) transferrin levels are reduced in patients with early multiple sclerosisM. Khalil, B. Riedlbauer, C. Langkammer, C. Enzinger, S. Ropele, T. Stojakovic, H. Scharnagl, V.

Culea, A. Petzold, J.J. Archelos, S. Fuchs, F. Fazekas (Graz, AT; Amsterdam, NL)

Abnormalities of the brain functional connectome in paediatric patients with multiple sclerosisM. Filippi, P. Valsasina, M. Absinta, S. Sala, V. Martinelli, A. Ghezzi, P. Veggiotti, A. Falini, G.

Comi, M.A. Rocca (Milan, Gallarate, Pavia, IT)

R2* as a potential MRI measure for demyelination in MS lesionsC. Langkammer, M. Khalil, C. Enzinger, D. Pinter, S. Fuchs, S. Ropele, F. Fazekas (Graz, AT)

Correlation of brain volume loss with multiple sclerosis duration, MRI activity and disability: impact of fingolimod across 3 phase III trialsF. Barkhof, J. Cohen, E.W. Radue, L. Kappos, P. Calabresi, D. Haering, N. Sfikas, P. Von

Rosenstiel, G. Francis (Amsterdam, NL; Cleveland, US; Basel, CH; Baltimore, US; East

Hanover, US)

Efficacy and safety of daclizumab high-yield process (DAC HYP) treatment in relapsing-remitting multiple sclerosis: results from the SELECTION extension

studyG. Giovannoni, R. Gold, K. Selmaj, E. Havrdova, X. Montalban, E.-W. Radue, D. Stefoski, M.

McNeill, J. Rana, J. Elkins, G. O'Neill (London, GB; Bochum, DE; Lodz, PL; Prague, CZ;

Barcelona, ES; Basel, CH; Chicago, US; Maidenhead, GB; Cambridge, US)

Effect of BG-12 (dimethyl fumarate) in newly diagnosed patients with relapsing-remitting multiple sclerosis from the DEFINE and CONFIRM studiesR. Gold, G. Giovannoni, J.T. Phillips, R.J. Fox, A. Zhang, L. Meltzer, N.C. Kurukulasuriya

(Bochum, DE; London, GB; Dallas, Cleveland, Weston, US)

Modifications of functional connectivity of the anterior cingulum correlate with medium-term effects of cognitive rehabilitation in patients with multiple

sclerosisL. Parisi, M.A. Rocca, M. Copetti, P. Valsasina, F. Mattioli, R. Capra, G. Comi, M. Filippi (Milan,

San Giovanni Rotondo, Brescia, IT)












Prof Giovannoni

Highlight

Prof Giovannoni

Highlight

Prof Giovannoni

Highlight

17:30 - 18:30 / POSTER SESSION 3 : CLINICAL NEUROPHYSIOLOGY II / POSTER AREA

17:30 - 18:30 / POSTER SESSION 3 : MULTIPLE SCLEROSIS: CLINICAL ASPECTS III / POSTER AREA










The "Sapere Migliora" information aid for newly-diagnosed multiple sclerosis patients: developing and testing phases following the MRC frameworkA. Giordano, A. Lugaresi, V. Martinelli, F. Granella, P. Confalonieri, M. Trojano, M. Messmer

Uccelli, C. Borreani, A. Solari on behalf of the SIMS project

Tongue somatosensory evoked potentials: evaluation of the afferent trigeminal pathway in patients with early multiple sclerosisM. Krbot Skoric, T. Gabelic, I. Adamec, M. Habek (Zagreb, HR)

Impaired deficit recognition in multiple sclerosisE. Reich, E. Arias, C. Torres, E. Halac, M. Kerszberg, M. Carlino (Caba, AR)

Risk-associated behaviour in multiple sclerosis: a case control studyC.H Haw kes, D. Boniface (London, GB)

Study of magnetisztion transfer MRI in clinically isolated syndromes (CIS)C. Oreja-Guevara, A. Royo, S. Noval, J. Alvarez-Linera (Madrid, ES)

Phenotype of neuromyelitis optica in the Czech RepublicP. Zbornikova, P. Nytrova, E. Havrdova, M. Tyblova, J. Lizrova Preiningerova, I. Kovarova, V.

Kral, E. Krasulova, M. Vaneckova, D. Horakova (Prague, Usti, CZ)

Development of a clinical practice guideline on the managment of multiple sclerosis using the GRADE methodological approachS. Otero-Romero, M.D. Estrada, J. Sastre-Garriga, M. Tintoré, A. Saiz, L.L. Ramió-Torrentà, D.

Benítez, M. Espallargues, X. Montalban (Barcelona, Girona, ES)

Rio score and modified Rio score validation in an Italian cohort of relapsing-remitting multiple sclerosis patientsA. Nuara, M. Romeo, V. Martinelli, M. Rodegher, S. Maida, E. Perego, G. Comi (Milan, IT)

Multiple sclerosis and extra central nervous system malignanciesI. Moreira, A. Martins Silva, E. Santos (Porto, PT)

Movement disorders in two multiple sclerosis centres in VenezuelaA. Soto, O Molina, M. Camacaro, I. Soto, M. Gallardo, R. León (Caracas, Maracaibo, Valencia,

VE)

Frequency of HLA DRB1 gene alleles in patients with multiple sclerosis and the importance of disease course in a Lithuanian populationR. Balnyte, D Rastenyte, A. Vaitkus, I. Urbonaviciute, A. Vitkauskiene, E. Skrodeniene (Kaunas,

LT)























Use of optical coherence tomography in multiple sclerosis patientsZ. Vladimirova, S. Cherninkova (Sofia, BG)

Birth outcomes in fathers with multiple sclerosisE. Lu, F. Zhu, Y. Zhao, M. van der Kop, A. Synnes, L. Dahlgren, A.D. Sadovnick, A.

Traboulsee, H. Tremlett (Vancouver, CA)

Investigation of central motor pathways in multiple sclerosis with transcranial magnetic stimulationK. Oikonomidi, V. Kimiskidis, S. Papagiannopoulos, M. Karagianni, O. Argiropoulou, E.

Koutsouraki, N. Vlaikidis (Thessaloniki, GR)

Lifetime hazard of patients with multiple sclerosis according to the database of the Department of Neurology at the University of Szeged between 1993 and

2013V. Zsiros, D. Sandi, J. Fuvesi, Z.T. Kincses, Z. Fricska-Nagy, M. Karacsony, H. Huszka, G.

Lencses, L. Vecsei, K. Bencsik (Szeged, HU)

Cognitive decline emerges beneath a critical threshold of total brain volume in patients with multiple sclerosis: support for the brain reserve hypothesisJ.F. Sumow ski, M.A. Rocca, V.M. Leavitt, G. Riccitelli, G. Comi, J. DeLuca, M. Filippi (West

Orange, US; Milan, IT)

Sensitivity of optical coherence tomography and visual evoked potentials in multiple sclerosisG. Di Maggio, B. Mariangela, R. Santangelo, L. Ferrari, S. Guerrieri, S. Medaglini, M. Rodegher,

B. Colombo, L. Moiola, U. Del Carro, V. Martinelli, G. Comi, L. Leocani (Milan, IT)

Event-related P300 potentials, cognitive impairment and brain atrophy in multiple sclerosis (MS)N. Tevzadze (Tbilisi, GE)

The evolution of visual evoked potentials (VEP) parameters in the course of multiple sclerosis (MS)B. Zakrzew ska-Pniew ska, M. Nojszew ska, B. Jakubiak-Mazur, Z. Lew andow ski (Warsaw ,

PL)

Rasch and traditional validation of the COSM-R, a questionnaire on satisfaction with communication of multiple sclerosis diagnosisA. Solari, M. Grzeda, A. Giordano, A. Simone, L. Vignatelli, K. Mattarozzi, R. D'Alessandro, L.

Tesio on behalf of the Agorà, GERONIMUS, SIMS-Trial and SIMS-Practice groups

Regional analysis of grey matter damage in African-Americans with multiple sclerosisM. Petracca, R. Teodorescu, J. How ard, L. Fleysher, N. Oesingmann, I. Katz-Sand, J. Herbert,

P. Carrieri, M. Inglese (Naples, IT; New York, US)

Female sexual dysfunction and sex hormone level during menstrual cycle in multiple sclerosis patientsS. Shahdaei, S. Rastyar, M. Moghadasi, F. Alipour, M. Norouzpour, M.A. Edalatmanesh (Fars,

Shiraz, IR)

Long-term health-related quality of life in Hungarian patients with multiple sclerosisJ. Füvesi, R. Januska, K. Bencsik, G. Lencsés, Z. Fricska-Nagy, E. Losonczi, C. Rajda, É.



















TUESDAY, JUNE 11, 2013

09:00 - 09:30 / SYMPOSIUM : PERSONALISED TREATMENT IN MULTIPLE SCLEROSIS / PLENARY HALL




11:30 - 12:30 / POSTER SESSION 4 : MULTIPLE SCLEROSIS: PATHOLOGY AND PATHOGENESIS / POSTER AREA

Langane, M. Török, L. Vécsei (Szeged, HU)

Which test is most suitable to assess cognitive impairment in multiple sclerosis? Comparison of neuropsychological standard tests and the paradigm ofvisual searchK.S. Utz, T.M.A. Hankeln, A. Waschbisch, D.-H. Lee, R.A. Linker, T. Schenk (Erlangen, DE)

The relationship between fatigue and severity of disability in multiple sclerosisM. Heidari, M. Akbarfahimi, S.M. Nabavi (Tehran, IR)

Does exercise improve cognitive function in multiple sclerosis? Report of a pilot studyB. Sangelaji, S.M. Nabavi (Tehran, IR)

Unmet needs of people with severe multiple sclerosis and their carers: qualitative data to construct a home palliative care programmeC. Borreani, E. Bianchi, S. Cilia, M. Giuntoli, E. Pietrolongo, I. Rossi, M.G. Grasso, F. Patti, L.

Lopes, A. Lugaresi, P. Confalonieri, P. Morino, L. Palmisano, G. Martino, M. Ponzio, R. Amadeo,

P. Zaratin, M.A. Battaglia, A. Giordano, A. Solari on behalf of the PeNSAMI project

Cerebrospinal fluid (CSF) free light chains: diagnostic and predictive relevance in multiple sclerosis and clinically isolated syndromeM. Senel, J. Brettschneider, H. Tumani (Ulm, DE)

Lower functional connectivity in the default network of memory-impaired patients with multiple sclerosis (MS)V.M. Leavitt, J. Paxton, J.F. Sumow ski (West Orange, US)

EfficacyG. Comi (Milan, IT)

SafetyA. Siva (Istanbul, TR)

Towards personalized medicine in Multiple SclerosisP. Soelberg Sorensen (Copenhagen, DK)

Shared decision-making and patient-centred careA. Solari (Milan, IT)

Oligoadenylate synthetase 1 gene polymorphism and disease activity of multiple sclerosisW. Fadel, E. El-seidy, K. Rashed, H. Mourad (Tanta, EG)



















11:30 - 12:30 / POSTER SESSION 4 : NEURO-EPIDEMIOLOGY / POSTER AREA




Genetic associations and clinical course of familial multiple sclerosis in Novosibirsk region of RussiaD. Korobko, N. Malkova, E. Sokolova, M. Filipenko (Novosibirsk, RU)

Surface expansion of the hippocampal dentate gyrus in multiple sclerosis: in vivo evidence of neurogenesis?P. Preziosa, G. Longoni, M.A. Rocca, E. Pagani, G. Riccitelli, B. Colombo, M. Rodegher, A. Falini,

G. Comi, M. Filippi (Milan, IT)

Dynamic patterns of grey and white matter atrophy in patients with clinically isolated syndrome suggestive of multiple sclerosis one year from first clinical

episodeP. Preziosa, M.A. Rocca, S. Mesaros, E. Pagani, D. Damjanovic, T. Stosic-Opincal, J. Drulovic,

M. Filippi (Milan, IT; Belgrade, RS)

Influence of depression and fatigue on the regional distribution of brain damage in patients with multiple sclerosisG. Riccitelli, M.A. Rocca, C. Gobbi, E. Pagani, P. Preziosa, V. Martinelli, M. Radaelli, G. Comi, M.

Filippi (Milan, IT)

The effect of immunomodulating therapies on cGMP concentration in brain cortex of experimental autoimmune encephalomyelitis (EAE)N. Lubina-Dabrow ska, G. Sulkow ski, B. Dabrow ska-Bouta, J. Langfort, A. Stepien, M.

Chalimoniuk (Warsaw , PL)

Microstructural damage to normal appearing white matter (NAWM) and grey matter (GM) but not to cortical lesions contributes to cognitive impairment in

multiple sclerosis: a diffusion tensor MRI studyM. Filippi, E. Pagani, M.E. Morelli, P. Preziosa, M. Copetti, D. Dalla Libera, V. Martinelli, A. Falini,

G. Comi, M.A. Rocca (Milan, San Giovanni Rotondo, IT)

Plasma adipocytokines and oral contraceptive use in patients with relapsing-remitting multiple sclerosisC. Capela, A. Sena, C. Nóbrega, A. Sousa, R. Roque, M. Cascais, V. Ferret-Sena, R. Pedrosa

(Lisbon, PT)

Demographic and clinical characteristics of multiple sclerosis patients in the Upper Silesia region of Poland: preliminary studyM. Adamczyk-Sow a, K. Pierzchala, K. Kubicka, P. Sow a (Zabrze, PL)

The prevalence of multiple sclerosis and dietary factors: an ecological study using data from the Food and Agriculture OrganisationK. Lauer (Griesheim, DE)

The importance of neutralizing antibodies in relapsing-remitting multiple sclerosisC. Baetu, R.E. Martin, I. Buraga (Bucharest, RO)

Natalizumab treatment influences peroxisome proliferator-activated receptors (PPARs) and CD36 receptor mRNA expression in patients with multiple

sclerosisA. Sousa, V. Ferret-Sena, I. Cavaleiro, A. Maia e Silva, G. Chinetti-Gbaguidi, B. Derudas, B.

Staels, J. Vale, M. Veloso, R. Pedrosa, A. Sena (Lisbon, PT; Lille, FR)






















11:30 - 12:30 / POSTER SESSION 4 : CHILD NEUROLOGY / POSTER AREA

PET study of pathogenesis of cognitive impairment in varying degrees of disability in patients with different types of multiple sclerosisG. Shkilnyuk, A. Ilves, G. Katayeva, L. Prakhova, I. Stolyarov (Saint Petersburg, RU)

FTY720 is neuroprotective after toxin-induced central nervous system demyelinationA. Slow ik, T. Schmidt, S. Amor, C. Beyer, M. Kipp (Aachen, DE)

Analysis of the integrity of the pyramidal tract (PT) in response to lesions in patients with clinically isolated syndrome (CIS)M. Paw litzki, J. Heidel, J. Kaufmann, E. Stadler, M. Sailer (Magdeburg, DE)

Who gets admitted to neurology beds? Experience from a tertiary referral centre in EgyptS. El Taw il, T. Emara, N. Kasim, A. Abdelhak (Cairo, EG)

Loss of brain tissue accompanied by decrease of processing speed: the main determinant of cognitive performance in patients with multiple sclerosis?E. Stadler, P. Bublak, R. Deppe, J. Feiss, M. Fischer, F. Hoffmann, A. Kunkel, M. Schw ab, K.

Voigt, U. Zettl, W. Köhler, M. Sailer (Magdeburg, Jena, Halle, Teupitz, Wermsdorf, Rostock, DE)

Predictors of disability extremes in patients with multiple sclerosis treated with interferon-beta using the Swedish multiple sclerosis registryK. Fink, A. Glaser, A. Fogdell-Hahn, J. Hillert (Stockholm, SE)

Comparing objective measures of neurodegeneration in multiple sclerosis (MS)V. Fernandez, M.J. Postigo, P. Urbaneja, A. Leon, A. Alonso, M. Guerrero, O. Fernandez

(Málaga, ES)

Prognostic value of cerebrospinal fluid (CSF) cytology in clinically isolated syndrome for subsequent progression to multiple sclerosisY. Motuzova, F. Granieri, P. Valentino, A. Sala, G. Amadore, A. Bertolotto (Minsk, BY;

Orbassano, IT)

Serum levels of apoptosis-related proteins in multiple sclerosis (MS) patientsM. Moreno, M. Sáenz-Cuesta, J. Castilló, E. Cantó, R. Nurtdinov, C. Tur, X. Montalban, M.

Comabella (Barcelona, ES)

No evidence for single nucleotide polymorphisms in the MMP9 gene conferring multiple sclerosis (MS) susceptibilityC. Wolf, S. Nischw itz, D. Buck, UK. Zettl, P. Rieckmann, B. Hemmer, M. Ising, S. Lucae, T.

Bettecken, B. Mueller-Myhsok, F. Weber (Munich, Rostock, Bamberg, DE)

Neurological comorbidities in children and adolescents with migraine headacheA. Potic, D. Momcilovic-Kostadinovic, D. Stupar, J. Vujovic, G. Tricomi (Belgrade, RS; Bologna,

IT)












11:30 - 12:30 / POSTER SESSION 4 : CHILD NEUROLOGY / POSTER AREA

16:15 - 17:00 / TEACHING COURSE 17 : MEASURING HETEROGENEITY IN MULTIPLE SCLEROSIS: THE MRI PERSPECTIVE / ROOM A

Demyelinating clinically isolated syndrome mimicking acute brainstem ischaemia in an eight year old child with patent foramen ovaleL. Ferrè, L. Moiola, M. Radaelli, V. Barcella, F. Sangalli, C. Baldoli, F. Triulzi, V. Martinelli, G.

Comi (Milan, IT)

Imaging the spinal cord in multiple sclerosis and clinical correlationsO. Ciccarelli (London, GB)



Ms related abstracts ens june 2013 barcelona

Health & Medicine

Transcript of Ms related abstracts ens june 2013 barcelona